Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Retatrutide is the unimolecular triple agonist furthest in development and data from phase 2 trials suggests that this may soon become the most potent weight-lowering pharmacotherapy to be licenced
There are no brand name medicines that lower total medical cost over a population, and generally health economists believe that drugs that cost less than $100,000 or $150,000 per QALY are high value. Implications for employers: The net cost of GLP-1 drugs is already just 42% of the list price, so a 50% list price cut might not lead to employer savings
When the patient's condition involves more than a structural problem, the options run out fast
Gottlieb DJ, Lederer DJ, Kim JS, et al
These effects contribute to weight loss that varies by agent and dosetypically ranging from 5-8% with liraglutide 3 mg (Saxenda), up to 15% with semaglutide 2.4 mg (Wegovy), and potentially up to 20% with higher doses of tirzepatide (Zepbound)
The marketing may describe the application and purpose commonly associated with Melanotan II (e.g
US$ 27.86
US$ 20.54
US$ 24.06
US$ 28.21
US$ 20.63
